Breast Biopsy Devices Market to reach USD 3.4 billion in 2030, at a CAGR of 9.7% | IMR

According to Intent Market Research, the Breast Biopsy Devices Market is expected to grow from USD 1.8 billion in 2023-e to touch USD 3.4 billion in 2030, growing at a CAGR of 9.7%. Increasing Investment in Clinical Trials and Research Expected to Foster the Growth in Breast Biopsy Market

A breast biopsy is a diagnostic procedure involving the removal of cells or tissue from the breast for microscopic examination by a pathologist. The examination provides crucial information about the breast tissue, aiding in the diagnosis and formulation of an appropriate treatment plan. Additionally, a biopsy can serve as a means to entirely remove small breast abnormalities when necessary.

Various types of biopsies are employed to extract samples of cells or tissue from the breast, each with its distinctions. These include the fine needle biopsy (FNA or FNAB), used for precise cell sampling, cyst aspiration for FNAB, core biopsy (CNB) or core needle biopsy, and vacuum-assisted core biopsy (VACB) or Mammotome.

The proliferation of breast cancer screening programs represents a significant catalyst for the breast biopsy devices market. National and community-level initiatives aimed at regular screening have substantially increased the number of individuals undergoing diagnostic procedures. This surge in screenings is fostering greater demand for breast biopsy devices, given their integral role in confirming or ruling out malignancies detected through screening.

Assay kits play a pivotal role in the breast biopsy devices market, contributing significantly to the precision and efficiency of diagnostic procedures. These kits are instrumental in the detection and analysis of specific molecular markers, proteins, or genetic components within breast tissue samples obtained through biopsy procedures. These kits provide a standardized and reliable platform for assessing biomarkers and molecular signatures associated with breast cancer, aiding in the accurate characterization of tissue samples. With advancements in technology and the growing emphasis on personalized medicine, assay kits have become essential tools for clinicians and pathologists.

The liquid biopsy technique is leading the market growth owing to the high accuracy achieved by image-guided procedures in localizing abnormal masses, surpassing non-image-guided alternatives. This precision enhances the segment's expansion, presenting advantageous opportunities in the business landscape.

Complex cysts features as thick walls, dense septa, intracystic masses, or other clearly defined solid components. These cysts, commonly found in women over the age of 40, are effectively detectable through breast ultrasound, with reported accuracy in diagnosis nearing 100%. The prevalence of breast cysts, coupled with the advanced diagnostic capabilities of ultrasound, propels the biopsy segment's growth, offering significant market space for expansion.

The breast biopsy devices market is characterized by the presence of various small and big players. The major market players include Argon Medical Devices, Becton Dickinson and Company, Cook Medical, Devicor Medical Products, F. Hoffmann-La Roche, GE Healthcare, Hologic, Leica Biosystems, Medax Srl, Planmed, Scion Medical Technologies, Siemens Healthier, amongst others.  In a competitive market landscape, players are swiftly embracing advanced technologies to enhance breast biopsy devices market operations and bolster their competitive stance through strategic initiatives, including mergers, acquisitions, and the introduction of new products.